Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytokinetics Ispinesib Could Help Fill Gap In HER2 Negative Breast Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cytokinetics is casting a wider net with its development program for ispinesib following the targeted oncologic’s failure earlier this year in a Phase II lung cancer trial.

You may also be interested in...

Cytokinetics takes on more ispinesib duties

Cytokinetics and GlaxoSmithKline have amended their agreement relating to development of Cytokinetics' kinase spindle protein inhibitors, including the Phase II oncologic ispinesib, Cytokinetics says Nov. 27. The San Francisco biotech plans "a focused development program for ispinesib" that builds on GSK's Phase I/II efforts with the compound. During a second quarter earnings call, CEO James Sabry said the firm would cast a wider net of trials in the wake of ispinesib's Phase II failure in lung cancer (1Pharmaceutical Approvals Monthly August 2006, p. 6)...

Cytokinetics oral heart failure agent begins Phase I

After releasing top-line results of its Phase I intravenous CK-1827452 candidate to treat acute and chronic heart failure, Cytokinetics announced it will begin Phase I trials of an oral formulation of the compound. The company hopes to study the intravenous formulation in acutely decompensated heart failure patients in a hospital setting and transition them to an oral dose in an outpatient setting. Cytokinetics is already considering a sales force of 100-200 full-time employees for the drug (1Pharmaceutical Approvals Monthly August 2006, p. 6)...

Genentech Stops Avastin Ovarian Cancer Trial Enrollment After GI Perforations

Genentech is discontinuing enrollment of a Phase II study of Avastin (bevacizumab) in platinum-refractory ovarian cancer patients due to an excessively high rate of reported gastrointestinal perforations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts